Nuvalent Inc Class A NUVL
News
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Nuvalent Announces Public Offering of Common Stock
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment